Start with the medical question and your priorities
Bring your weight history, previous approaches, current diagnoses and a complete medicine and supplement list. Describe the support you want and any practical barriers, such as travel, cost or access to appointments. Ask who will assess and prescribe, what information they need and whether another member of your care team should be involved. The consultation helps establish an appropriate next step; an ingredient name or program price does not establish personal suitability.
Separate the ingredient from the finished product
Semaglutide is not a single universal route or schedule. Current FDA labeling for Wegovy includes injectable and tablet formulations. Ask which exact product and formulation are being considered, the intended purpose and the instructions that would accompany that prescription. A semaglutide program name does not establish which preparation a clinic will supply. Keep the actual patient labeling and contact details with the written plan.
Clarify approval, compounding and alternatives
FDA distinguishes Zepbound’s weight-management indication from Mounjaro’s diabetes indication, although both contain tirzepatide. Ingredient identity does not make a compounded preparation an approved brand equivalent. Compounded GLP-1 products are not FDA-approved; FDA has identified dosing and quality concerns. Ask whether the proposed finished medicine is approved or compounded, who dispenses it, and who will explain its label and instructions. Confirm the reason for the proposal and the alternatives before deciding.
Ask about suitability rather than assuming eligibility
Discuss the actual medicine’s warnings, your history, other medicines, pregnancy plans and planned procedures with the prescriber. An assessment does not guarantee a prescription.
Choose useful review questions
Agree on the goals you want to discuss and how progress would be evaluated. Ask which measures are relevant, when a review would be useful and what could change the plan. General trial percentages and online timelines do not describe your own outcome or establish results from Rani’s program. Bring questions about tolerability, daily functioning and access as well as weight change. Keep the agreed review points in writing so later decisions have a clear basis.
Know the warnings and the contact for concerns
Read the actual product’s Medication Guide with the prescriber. Confirm the responsible clinician’s contact and after-hours instructions. Tests and appointments cannot guarantee safety; keep prescription-specific instructions with your written plan.
Confirm the support and ongoing review plan
Ask what nutrition, activity and other support is actually offered, who provides it and which charges apply. Discuss practical needs rather than copying a protein, exercise or hydration target from a general guide. Duration depends on response and adverse effects; some weight-management medicines may be used long-term, and weight regain can occur after stopping. Ask how ongoing need, access changes and a possible transition would be reviewed. Do not assume a routine taper or low-dose maintenance phase.
Keep the medical appointment and monthly quote distinct
The Medical Weight-Management Consultation is $149 for the initial appointment. The menu lists liraglutide at $249–349, semaglutide at $349–549 and tirzepatide at $449–699 per month. The prescribed plan determines the amount and written inclusions. Ask which medication, visits, tests and other charges the quote covers. Monthly program arrangements are confirmed with the clinic. General wellness injections are intramuscular (IM); that separate category does not determine the route of a weight-management prescription. The named medical assessment is distinct from an aesthetic consultation or AURA scan.